Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Bendamustine

Nature Reviews Drug Discovery volume 7, pages 473–474 (2008)Cite this article

Chronic lymphocytic leukaemia (CLL), which results from the production of long-lived abnormal lymphocytes, is the most common type of leukaemia in North America and Europe1. It mainly affects the elderly, and has a highly variable course, with survival ranging from months to decades1.

Most patients with CLL are now identified through blood tests that have been performed for unrelated reasons rather than because of signs or symptoms of the disease, and approximately a third of patients never need treatment1. Standard management of most patients has therefore traditionally involved a period of watchful waiting to see if the disease progresses1. However, there is currently a focus on modifying this strategy as understanding of potential prognostic factors improves1.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: DNA alkylating anticancer drugs.

References

  1. Dighiero, G. & Hamblin, T. J. Chronic lymphocytic leukaemia. Lancet 371, 1017–1029 (2008).

    Article  CAS  PubMed  Google Scholar 

  2. Lin, T. S. et al. Changing the way we think about chronic lymphocytic leukemia. J. Clin. Oncol. 23, 4009–4012 (2005).

    Article  PubMed  Google Scholar 

  3. Chabber, B. A. & Roberts, T. G. Jr. Chemotherapy and the war on cancer. Nature Rev. Cancer 5, 65–72 (2005).

    Article  Google Scholar 

  4. Leoni, L. M. et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin. Cancer Res. 14, 309–317 (2008).

    Article  CAS  PubMed  Google Scholar 

  5. Bergmann, M. A. et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica 90, 1357–1364 (2005).

    CAS  PubMed  Google Scholar 

  6. Food and Drug Administration. FDA labelling information [online], (2008).

  7. Keating, M. J. et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 74, 19–25 (1989).

    CAS  PubMed  Google Scholar 

  8. Hillmen, P. et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 25, 5616–5623 (2007).

    Article  CAS  PubMed  Google Scholar 

  9. Byrd, J. C. et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101, 6–14 (2003).

    Article  CAS  PubMed  Google Scholar 

  10. Tam, C. et al. Long-term results of the fludarabine, cyclophosphamide and rituximab regimen as an initial therapy of chronic lymphocytic leukemia. Blood (in the press).

  11. Morton, L. M. et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 107, 265–276. (2006)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. National Cancer Institute. Cancer statistics [online],.

  13. IMS Oncology Analyzer (2008).

Download references

Author information

Authors and Affiliations

  1. Michael J. Keating is at the Department of Leukemia, MD Anderson Cancer Center, PO Box 301402, Houston, Texas 77025, USA. mkeating@mdanderson.org,

    Michael J. Keating

  2. Uma Yasothan and Christian Bach are at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK. UYasothan@de.imshealth.com,

    Christian Bach & Uma Yasothan

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery. p.kirkpatrick@nature.com,

    Peter Kirkpatrick

Authors
  1. Michael J. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christian Bach
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Uma Yasothan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Keating, M., Bach, C., Yasothan, U. et al. Bendamustine. Nat Rev Drug Discov 7, 473–474 (2008). https://doi.org/10.1038/nrd2596

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2596

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing